Lasilactone contains a short-acting diuretic and a long-acting aldosterone antagonist. It is indicated in the treatment of resistant oedema where this is associated with secondary hyperaldosteronism; conditions include chronic congestive cardiac failure and hepatic cirrhosis. Treatment with Lasilactone should be reserved for cases refractory to a diuretic alone at conventional doses. This fixed ratio combination should only be used if titration with the component drugs separately indicates that this product is appropriate. The use of Lasilactone in the management of essential hypertension should be restricted to patients with demonstrated hyperaldosteronism. It is recommended that in these patients also, this combination should only be used if titration with the component drugs separately indicates that this product is appropriate.
Cempra has announced the publication of positive results from its pivotal Phase III clinical trial of Solitaire (solithromycin oral capsules)...